Sir,

Chronic hemodialysis (CHD) patients are vulnerable to infections, including infections by methicillin-resistant staphylococci (MRS) because they are repeatedly exposed to the hospital environment and often receive prolonged courses of antibiotics, besides being immunocompromised[@ref1]. Nasal carriage of MRS in hospital personnel also adds to the colonization pressure in healthcare facilities, acting as reservoirs for transmission to these patients[@ref1]. Routine use of mupirocin and chlorhexidine in healthcare settings has contributed to acquisition of resistance to these antimicrobial agents among microbes which cause outbreaks in these settings[@ref2]. Resistance to mupirocin is of low-level (mutations in the chromosomal *ileS* gene) or high-level \[by a plasmid-mediated *mupA* (*ileS2*) gene, encoding a novel IleS\][@ref3]. Chlorhexidine resistance is conferred by the plasmid- mediated *qacA/B* genes which encode proton-dependent multidrug efflux pumps[@ref4]. We conducted a cross-sectional study to detect the presence of mupirocin and chlorhexidine resistance among methicillin resistant staphylococcal isolates obtained from the dialysis unit of a tertiary care hospital.

A total of 83 non-duplicate methicillin resistant coagulase negative staphylococcal (MRCoNS) isolates from anterior nares of CHD patients (*n*=124) and hospital personnel (*n*=30) from dialysis unit of Billroth Hospital, a tertiary care centre in Chennai, Tamil Nadu, India, were included in this study. Phenotypic detection of low- and high-level mupirocin resistance was carried out using mupirocin discs \[5 and 200 μg (Hi-Media, Mumbai)\] and minimum inhibitory concentration (MIC) for mupirocin was determined by agar dilution method[@ref5][@ref6]. *Staphylococcus aureus* ATCC 25923 was used as quality control strain and results were interpreted as per Clinical and Laboratory Standards Institute (CLSI) guidelines and British Society for Antimicrobial Chemotherapy (BSAC) guidelines[@ref5][@ref6]. Isolates resistant to 5 and 200 μg mupirocin discs were further subjected to *mupA* gene detection[@ref7]. All isolates were screened for the presence of chlorhexidine resistance gene (*qacA/B*) by PCR[@ref8].

Of the 83 MRCoNS isolates, 68 (81.9%) were from CHD patients and 15 (18%) from dialysis unit staff members. Mupirocin resistance was observed in 26 (31.3%) isolates, of which, 22 (26.5%) exhibited high-level mupirocin resistance (HLMR) and were also positive for *mupA* gene. In our study, mupirocin resistance was slightly higher than that reported from another study from south India[@ref9]. Majority of the isolates showing HLMR (*n*=16, 19.2%) were isolated from CHD patients. Six of 22 (27.3%) isolates with HLMR displayed *qacA/B*. The distribution of chlorhexidine resistance genes among high- and low-level mupirocin resistant and mupirocin sensitive isolates are shown in the [Table](#T1){ref-type="table"}. In this study, mupirocin sensitive isolates (12/83, 14.4%) were found to harbour higher percentage of *qacA/B* genes compared to mupirocin resistant isolates (8/83, 9.6%).
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In conclusion, our findings indicate that the routine use of chlorhexidine and mupirocin prophylaxis may increase the prevalence of chlorhexidine- and mupirocin-resistance genes in staphylococci in a hospital setting.
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